跳至主要内容
临床试验/JPRN-UMIN000027851
JPRN-UMIN000027851已完成未知

Efficacy and safety of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b with chronic kidney disease(eGFR30-60ml/min/1.73m2) - Efficacy and safety of Ledipasvir/Sofosbuvir in patient with chronic kidney disease

ippon Medical School Chiba Hokusoh Hospital0 个研究点目标入组 700 人开始时间: 2017年6月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.History of allergy to Ledipasvir and Sofosbuvir. 2.Decompensated liver cirrhosis 3.pregnant woman or lactating mother 4.Hepatocellular carcinoma, or other malignant tumor. 5.severe depression 6.Judged by investigator not to be appropriate for inclusion in this study 7.Patient with dialysis or patients with severe renal function disorder (eGFR<30ml/min/1.73m2) 8.Receiving contraindicated drugs for Ledipasvir and Sofosbuvir combined therapy

研究者

发起方
ippon Medical School Chiba Hokusoh Hospital

相似试验